Illuccix Gets Expanded FDA Approval for Imaging of Metastatic Prostate Cancer
The expanded indication could facilitate improved access to imaging for patients with metastatic prostate cancer who are candidates for radioligand treatment.
The Food and Drug Administration (FDA) has approved an expanded indication for Illuccix® (Telix Pharmaceuticals) that allows use of the gallium GA 68 gozetotide injection preparation kit for PSMA-guided PET imaging of metastatic prostate cancer to help determine whether patients are candidates for radioligand therapy.1
In order for patients to be considered as viable candidates for targeted radioligand treatment, they need to undergo imaging with an approved gallium-based prostate-specific membrane antigen (PSMA) positron emission tomography (PET) agent, according to Telix Pharmaceuticals. The company added that Pluvicto® (Novartis) is currently the only FDA-approved PSMA-directed radioligand treatment.
“As radioligand therapy for prostate cancer becomes more prevalent, it is critical for doctors to understand who may or may not respond to those treatments. There’s no doubt that appropriate selection of patients for PSMA-targeted radioligand therapy is dependent on appropriate imaging,” emphasized Oliver Sartor, M.D., a professor of medicine and the director of the Tulane Cancer Center at the Tulane University School of Medicine in New Orleans.
(Editor’s note: For related content, see “Recurrent Prostate Cancer and Low PSA Levels: Can an Emerging PSMA PET Agent Have an Impact?” and “Could an Emerging PSMA/PET Imaging Agent Improve the Detection of Recurrent Prostate Cancer?”)
Telix Pharmaceuticals said findings from the phase 3 VISION trial demonstrated the ability of Illuccix to aid in the detection of prostate cancer and help identify patients who may benefit from PSMA-based radioligand therapy.
“Ga-68 PSMA-11 PET was used in the VISION trial and, when used in combination with contrast-enhanced CT, represents a powerful tool for detecting prostate cancer and helping guide patient management,” noted Dr. Sartor, the lead author of the VISION study.2
References
1. Telix Pharmaceuticals Limited. FDA approves expanded indication for Telix’s Illuccix® to include patient selection for PSMA-directed radioligand therapy. Cision PR Newswire. Available at: https://www.prnewswire.com/news-releases/fda-approves-expanded-indication-for-telixs-illuccix-to-include-patient-selection-for-psma-directed-radioligand-therapy-301773819.html . Published March 16, 2023. Accessed March 16, 2023.
2. Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091-1103.
Can AI Improve Detection of Extraprostatic Extension on MRI?
December 4th 2023Utilizing a deep learning-based AI algorithm to differentiate between diagnostic and non-diagnostic quality of prostate MRI facilitated a 10 percent higher specificity rate for diagnosing extraprostatic extension on multiparametric MRI, according to research presented at the recent RSNA conference.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Do Bone Scans Over Stage Prostate Cancer? What a Multicenter Study Reveals
November 16th 2023Fifty-seven percent of patients with prostate cancer diagnosed with osseous metastases on bone scans had negative findings on PSMA PET imaging, according to findings from an international multicenter comparative study.
Can MRI Findings Help Predict Toxicity After Radiotherapy for Prostate Cancer?
October 23rd 2023Emerging research findings suggest that a longer prostatic urethral length on MRI is associated with a 70 percent increased risk of grade >2 acute urinary toxicity after radiotherapy for prostate cancer.
Multinational Study Suggests High Variability with Quality of Prostate MRI
October 12th 2023In a study of 355 multiparametric prostate MRI exams from a total of 71 scanners from 41 facilities in 18 countries, researchers found that only 23 scanners achieved a PI-QUAL score of 5 for optimal image quality.
